• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Shift Technologies Shares Are Trading Lower By 15%; Here Are 20 Stocks Moving Premarket

    3/29/23 8:05:56 AM ET
    $ARCT
    $AULT
    $BDRX
    $BRDS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Machinery/Components
    Technology
    Get the next $ARCT alert in real time by email

    Gainers

    • LogicMark, Inc. (NASDAQ:LGMK) shares rose 36.7% to $0.1914 in pre-market trading after the company reported strong revenue and margin growth for the year ended 2022.
    • Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) gained 36.3% to $0.6758 in pre-market trading. Biodexa Pharmaceuticals reported exercise of warrants and issue of equity.
    • Helbiz, Inc. (NASDAQ:HLBZ) gained 23.3% to $0.1419 in pre-market trading. Helbiz posted FY22 revenue of $15.5 million, up 21% year over year.
    • Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) climbed 22.5% to $19.00 in pre-market trading after the company reported upbeat fourth-quarter results and provided an update on pipeline progress.
    • Bird Global, Inc. (NASDAQ:BRDS) rose 18.1% to $0.2288 in pre-market after jumping 42% on Tuesday.
    • Cipher Mining Inc. (NASDAQ:CIFR) gained 14.7% to $2.18 in pre-market trading.
    • Lululemon Athletica Inc (NASDAQ:LULU) shares rose 14.4% to $366.53 in pre-market trading as the company reported better-than-expected Q4 results and issued strong forecast.
    • N-able, Inc. (NYSE:NABL) shares rose 13.6% to $13.80 in pre-market trading. N-able will replace iStar Incin the S&P SmallCap 600 on Monday, April 3.
    • Pyxis Oncology, Inc. (NASDAQ:PYXS) rose 9.9% to $4.23 in pre-market trading after jumping over 42% on Tuesday. Pyxis Oncology recently reported a loss of $3.65 per share in FY22.
    • Emergent BioSolutions Inc (NYSE:EBS) shares rose 7.8% to $9.59 in pre-market trading. Emergent BioSolutions, last month, posted a Q4 loss of $0.31 per share.

    Losers

    • Draganfly Inc. (NASDAQ:DPRO) fell 17.5% to $1.18 in pre-market trading. Draganfly reported a proposed underwritten public offering to secure growth capital.
    • Shift Technologies, Inc (NASDAQ:SFT) shares dropped 14.8% to $1.43 in pre-market trading after reporting downbeat quarterly sales. Shift also announced regaining compliance with Nasdaq listing requirement.
    • SomaLogic, Inc. (NASDAQ:SLGC) fell 14.5% to $2.00 in pre-market trading after the company posted a wider-than-expected Q4 loss.
    • Minim, Inc. (NASDAQ:MINM) fell 11.9% to $0.1262 in pre-market ahead of quarterly earnings.
    • Sono Group N.V. (NASDAQ:SEV) fell 8.7% to $0.3150 in pre-market trading after declining around 7% on Tuesday. Sono Group recently received Nasdaq notification regarding minimum bid price deficiency.
    • Oriental Culture Holding LTD (NASDAQ:OCG) shares fell 6.7% to $0.41 in pre-market trading.
    • FOXO Technologies Inc. (NYSE:FOXO) fell 5.9% to $0.32 in pre-market trading. FOXO Technologies is expected to report financial results for the fourth quarter after the closing bell on Thursday, March 30, 2023.
    • Ault Alliance, Inc. (NYSE:AULT) shares fell 5.2% to $0.0920 in pre-market trading after gaining around 4% on Tuesday.
    • Unity Biotechnology, Inc. (NASDAQ:UBX) fell 4.6% to $1.67 in pre-market trading. Unity Biotechnology recently said its phase 2 ENVISION study did not meet its non-inferiority threshold due to strength in the control group.
    • IceCure Medical Ltd (NASDAQ:ICCM) fell 4.6% to $1.22 in pre-market trading after gaining 14% on Tuesday. IceCure Medical secured regulatory approval in China for commercial use of its IceSense3 Disposable Cryoprobes.

    Now Read This: Check Out 3 High-Yielding Dividend Stocks In Industrials Sector From Wall Street's Most Accurate Analysts

    Get the next $ARCT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARCT
    $AULT
    $BDRX
    $BRDS

    CompanyDatePrice TargetRatingAnalyst
    Cipher Mining Inc.
    $CIFR
    2/9/2026$38.00Overweight
    Morgan Stanley
    N-able Inc.
    $NABL
    1/23/2026$10.00Buy
    B. Riley Securities
    Arcturus Therapeutics Holdings Inc.
    $ARCT
    1/23/2026$20.00Buy
    Roth Capital
    lululemon athletica inc.
    $LULU
    1/8/2026Hold
    Deutsche Bank
    lululemon athletica inc.
    $LULU
    12/12/2025$170.00Underperform → Hold
    Jefferies
    lululemon athletica inc.
    $LULU
    12/12/2025$200.00 → $215.00Market Perform
    Telsey Advisory Group
    lululemon athletica inc.
    $LULU
    12/10/2025Neutral
    Guggenheim
    Cipher Mining Inc.
    $CIFR
    11/24/2025$18.00Neutral → Overweight
    Analyst
    More analyst ratings

    $ARCT
    $AULT
    $BDRX
    $BRDS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley initiated coverage on Cipher Mining with a new price target

    Morgan Stanley initiated coverage of Cipher Mining with a rating of Overweight and set a new price target of $38.00

    2/9/26 7:01:11 AM ET
    $CIFR
    Finance: Consumer Services
    Finance

    B. Riley Securities initiated coverage on N-able with a new price target

    B. Riley Securities initiated coverage of N-able with a rating of Buy and set a new price target of $10.00

    1/23/26 8:20:35 AM ET
    $NABL
    Computer Software: Prepackaged Software
    Technology

    Roth Capital initiated coverage on Arcturus Therapeutics with a new price target

    Roth Capital initiated coverage of Arcturus Therapeutics with a rating of Buy and set a new price target of $20.00

    1/23/26 8:16:17 AM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARCT
    $AULT
    $BDRX
    $BRDS
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Cipher Mining Inc.

    SCHEDULE 13G/A - Cipher Mining Inc. (0001819989) (Subject)

    2/12/26 4:51:52 PM ET
    $CIFR
    Finance: Consumer Services
    Finance

    SEC Form EFFECT filed by FOXO Technologies Inc.

    EFFECT - FOXO TECHNOLOGIES INC. (0001812360) (Filer)

    2/12/26 12:15:28 AM ET
    $FOXO
    Life Insurance
    Finance

    Cipher Mining Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Cipher Mining Inc. (0001819989) (Filer)

    2/11/26 4:37:21 PM ET
    $CIFR
    Finance: Consumer Services
    Finance

    $ARCT
    $AULT
    $BDRX
    $BRDS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray Multipacks

    Approval will broaden the NARCAN® Nasal Spray portfolio, and improve cost-effectiveness by increasing flexibility and distribution efficiency of this life-saving medication  GAITHERSBURG, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions (NYSE:EBS) announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for new multipack configurations of over-the-counter (OTC) NARCAN® Nasal Spray. This approval expands the NARCAN® Nasal Spray product suite to include 6-count and 24-count multipack options, specifically designed to meet the needs of partners distributing higher volumes of naloxone. These new formats offer enhan

    2/12/26 6:00:00 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    GAITHERSBURG, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, February 26, 2026, at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year of 2025. Participants can access the conference call live via webcast and also by visiting the Investors page of Emergent's website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of

    2/12/26 9:02:20 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    N-able Empower 2026 to Take Place in Fort Lauderdale

    The annual conference returns this April to dive deep into business resilience N-able, Inc. (NYSE:NABL), a global cybersecurity company delivering business resilience, today announced Empower 2026 will take place in Fort Lauderdale from April 13-15, 2026, at the Omni Hotel. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260212315699/en/Empower 2026 As AI continues to fuel stronger and smarter attacks, building business resilience is an ongoing process. This event will shine a spotlight on what's working, what's falling short, and what's on the horizon in cybersecurity. Over three dynamic days, technology leaders, security prof

    2/12/26 7:02:00 AM ET
    $NABL
    Computer Software: Prepackaged Software
    Technology

    $ARCT
    $AULT
    $BDRX
    $BRDS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Chief Financial Officer Sassine Andy bought $20,499 worth of shares (1,238 units at $16.56), increasing direct ownership by 0.56% to 221,764 units (SEC Form 4)

    4/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)

    8/20/25 4:01:44 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Sassine Andy decreased direct ownership by 0.56% to 221,764 units (SEC Form 4)

    4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)

    8/19/25 4:05:30 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Papa Joseph C bought $349,800 worth of shares (60,000 units at $5.83), increasing direct ownership by 21% to 342,500 units (SEC Form 4)

    4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

    5/15/25 4:02:40 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARCT
    $AULT
    $BDRX
    $BRDS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, General Counsel, Corp Sec Perl Jessica covered exercise/tax liability with 918 shares, decreasing direct ownership by 1% to 67,469 units (SEC Form 4)

    4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

    2/10/26 7:11:20 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Quality & Ethics, and CPL Glessner Coleen returned $315,009 worth of shares to the company (28,847 units at $10.92) and covered exercise/tax liability with 2,852 shares, decreasing direct ownership by 22% to 112,620 units (SEC Form 4)

    4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

    2/10/26 7:09:25 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, Products Business Williams Paul Anthony returned $94,513 worth of shares to the company (8,655 units at $10.92) and covered exercise/tax liability with 1,022 shares, decreasing direct ownership by 11% to 76,194 units (SEC Form 4)

    4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

    2/10/26 7:07:24 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARCT
    $AULT
    $BDRX
    $BRDS
    Leadership Updates

    Live Leadership Updates

    View All

    Cipher Welcomes Thomas Duda to the Company's Board of Directors

    NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Cipher Mining Inc. (NASDAQ:CIFR) ("Cipher" or the "Company"), a leading developer and operator of industrial-scale data centers, today announces the appointment of Thomas Duda to its Board of Directors. Mr. Duda has more than twenty years of real estate-focused investment experience, further strengthening the Board as Cipher executes its pivot to becoming a world leader in data center development and operations. Mr. Duda currently serves as Vice President of Real Estate at Henry Crown and Company, where he leads the firm's real estate investment and asset management activities, and is a member of the Investment and Management Committee. Previous

    2/11/26 4:05:00 PM ET
    $CIFR
    Finance: Consumer Services
    Finance

    IceCure Announces Planned Departure of CFO Following Nine Years of Service and Key Milestones Achieved

    Ronen Tsimerman will continue as CFO until successor is appointed CAESAREA, Israel, Feb. 9, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), a developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that after nearly a decade of service with IceCure, Chief Financial Officer Ronen Tsimerman has informed the Company of his decision to leave the Company to pursue new opportunities. The Company has initiated a search for a new Chief Financial Officer and has identified compelling candidates with significant experience commercializing disruptive technolo

    2/9/26 4:30:00 PM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity

    BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a leadership transition to continue execution and advancement of the Company's strategic and clinical goals. Thomas Civik, a member of Pyxis Oncology's Board of Directors since the Company's IPO and a highly experienced biotechnology executive with a proven track record in advancing cancer therapeutics, has been appointed Interim Chief Executive Officer, effective immediately. Lara S. Sullivan, M.D., has stepped down from her roles as President, Chief Executive Officer and Chief Medical Officer. With

    2/3/26 6:45:00 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARCT
    $AULT
    $BDRX
    $BRDS
    Financials

    Live finance-specific insights

    View All

    Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    GAITHERSBURG, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, February 26, 2026, at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year of 2025. Participants can access the conference call live via webcast and also by visiting the Investors page of Emergent's website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of

    2/12/26 9:02:20 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cipher Mining Announces Date of Fourth Quarter and Full Year 2025 Business Update Conference Call

    NEW YORK, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Cipher Mining Inc. (NASDAQ:CIFR) ("Cipher" or the "Company") today announced it will provide a business update and release its fourth quarter and full year 2025 financial results before U.S. markets open on Tuesday, February 24th, 2026. Cipher will host a conference call and webcast that day at 8:00 a.m. Eastern Time. The live webcast and a webcast replay of the conference call can be accessed from the investor relations section of Cipher's website at https://investors.ciphermining.com. About CipherCipher is focused on the development and operation of industrial-scale data centers for bitcoin mining and HPC hosting. Cipher aims to be a market l

    2/9/26 4:05:00 PM ET
    $CIFR
    Finance: Consumer Services
    Finance

    N-able to Host Fourth Quarter Earnings Conference Call on February 19, 2026

    N-able, Inc. (NYSE:NABL), a global cybersecurity company delivering business resilience, today announced that it will host a conference call to discuss its financial results for the fourth quarter and full-year 2025 at 8:30 a.m. ET on February 19, 2026. A live webcast of the call will be available on the N-able Investor Relations website at http://investors.n-able.com. A replay of the webcast will be available on a temporary basis shortly after the event. N-able will issue its earnings release highlighting its fourth quarter and full-year 2025 results prior to the start of the conference call on February 19, 2026. About N-able N-able protects businesses from evolving cyberthreats. Our

    2/5/26 4:30:00 PM ET
    $NABL
    Computer Software: Prepackaged Software
    Technology

    $ARCT
    $AULT
    $BDRX
    $BRDS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by LogicMark Inc.

    SC 13D/A - LogicMark, Inc. (0001566826) (Subject)

    12/3/24 3:35:39 PM ET
    $LGMK
    Industrial Specialties
    Health Care

    Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

    SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

    11/20/24 11:56:39 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Minim Inc.

    SC 13D/A - MINIM, INC. (0001467761) (Subject)

    11/15/24 5:00:07 PM ET
    $MINM
    Telecommunications Equipment
    Utilities